ProMIS Neurosciences Inc. - Common Shares (PMN)
1.1200
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 22nd, 6:46 AM EDT
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · July 21, 2025
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.
Via Chartmill · July 21, 2025
On Monday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · July 21, 2025
Via Benzinga · July 21, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · July 21, 2025
Via Benzinga · July 8, 2025
Via Benzinga · May 12, 2025

Via Benzinga · September 19, 2024

Via Benzinga · September 19, 2024

Via Benzinga · August 19, 2024

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
Via InvestorPlace · August 12, 2024

Via Benzinga · August 12, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 15, 2024

Via Benzinga · July 26, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30.
Via Benzinga · April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Via Benzinga · April 15, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 1, 2024

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The S&P 500, also fell, dropping, 0.11% to 4,394.78.
Via Benzinga · August 22, 2023

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
Via Benzinga · January 19, 2024

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
Via Benzinga · August 22, 2023

Via Benzinga · October 3, 2023

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Via Benzinga · August 22, 2023

We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!
Via InvestorPlace · August 22, 2023